title: Investor Outlook: Solving Gene Therapy Pricing…with a Cures Voucher?
abstract: Gene therapy reimbursement continues to be an intense topic of discussion in the field given the unique and durable benefits from a single administration and generally small patient populations against a reimbursement framework that is not optimized for such "cures" or long-lived benefits. As more gene therapy programs enter the market and late-stage development, it is increasingly important for the field to define a reimbursement model that works for all stakeholders in order to encourage the next wave of innovation. To add to the discussion around new payment models and potential solutions, we propose a flexible voucher system that takes advantage of existing infrastructure, precedent, and regulatory frameworks.
authors.affiliation: Piper Jaffray & Co. , New York, New York.
authors.forename: Joshua
authors.initials: J
authors.lastname: Schimmer
authors.affiliation: Piper Jaffray & Co. , New York, New York.
authors.forename: Steven
authors.initials: S
authors.lastname: Breazzano
mesh_terms: D003365:Costs and Cost Analysis; D004345:Drug Industry / Q000191:economics*; D015316:Genetic Therapy / Q000191:economics*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007449:Investments / Q000191:economics*